
|Articles|March 1, 2002
FDA Briefs - March 1, 2002
Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
2
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
3
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
4
Study maps thermal dynamics of glaucoma laser treatments
5















































.png)


